

PATENT  
454313-2338.1**AMENDMENT**

Please amend the claims without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

**In the Claims**

1-37. (Cancelled)

38. (Currently amended) A vaccine for eliciting a protective ~~an immunological~~ response against ~~porcine parvovirus and~~ porcine circovirus type II infection comprising at least one porcine parvovirus antigen and at least one inactivated porcine circovirus type II antigen, and a veterinarily acceptable vehicle or excipient.

39. (Cancelled)

40. (Currently amended) ~~[[A]] The vaccine of claim 38, wherein the porcine parvovirus antigen is selected from the group consisting of an attenuated porcine parvovirus, an inactivated porcine parvovirus, a subunit of porcine parvovirus, and a vector that contains and expresses in vivo a nucleic acid molecule encoding the porcine parvovirus antigen; and the porcine circovirus antigen is selected from the group consisting of an attenuated porcine circovirus, an inactivated porcine circovirus, a subunit of porcine circovirus, and a vector that contains and expresses in vivo a nucleic acid molecule encoding the porcine circovirus antigen.~~

41. (Cancelled)

42. (Currently amended) ~~[[A]] The vaccine of claim [[39]] 38,~~ wherein the porcine circovirus type II antigen is at least one antigen of a porcine circovirus type II deposited at the ECACC selected from group consisting of: porcine circovirus type II accession No. V97100219, porcine circovirus type II accession No. V97100218, porcine circovirus type II accession No. V97100217, porcine circovirus type II accession No. V98011608, and porcine circovirus type II accession No. V98011609.

43. (Currently amended) ~~[[A]] The vaccine of claim 38,~~ wherein the vaccine further comprises an additional antigen of another porcine pathogen.

44. (Currently amended) ~~[[A]] The vaccine of claim 43,~~ wherein the additional antigen of another porcine pathogen is selected from the group consisting of: an antigen of PRRS virus, an antigen of *Mycoplasma hypopneumoniae*, an antigen of *Actinobacillus pleuropneumoniae*, an antigen of *E. coli*, an antigen of Atrophic Rhinitis, an antigen of

PATENT  
454313-2338.1

Pseudorabies virus, an antigen of Hog cholera, an antigen of Swine Influenza, and combinations thereof.

45. (Currently amended) ~~[[A]]~~ The vaccine of claim 43, wherein the additional antigen of another porcine pathogen is an antigen of PRRS virus.

46-67. (Cancelled)

68. (Previously presented) A composition for eliciting a protective immunological response against porcine parvovirus and an immunological response against porcine circovirus comprising at least one porcine parvovirus antigen and at least one porcine circovirus antigen, and a veterinarily acceptable vehicle or excipient.

69. (Currently amended) ~~A vaccine~~ The composition of claim 68 wherein the porcine circovirus antigen comprises at least one porcine circovirus type II antigen.

70. (Currently amended) ~~A vaccine~~ The composition of claim 68 wherein the porcine parvovirus antigen is selected from the group consisting of an attenuated porcine parvovirus, an inactivated porcine parvovirus, a subunit of porcine parvovirus, and a vector that contains and expresses *in vivo* a nucleic acid molecule encoding the porcine parvovirus antigen; and the porcine circovirus antigen is selected from the group consisting of an attenuated porcine circovirus, an inactivated porcine circovirus, a subunit of porcine circovirus, and a vector that contains and expresses *in vivo* a nucleic acid molecule encoding the porcine circovirus antigen.

71. (Currently amended) ~~A vaccine~~ The composition of claim 69 wherein the porcine circovirus type II antigen is at least one antigen of a porcine circovirus type II deposited at the ECACC selected from group consisting of: porcine circovirus type II accession No. V97100219, porcine circovirus type II accession No. V97100218, porcine circovirus type II accession No. V97100217, porcine circovirus type II accession No. V98011608, and porcine circovirus type II accession No. V98011609.

72. (Currently amended) ~~A vaccine~~ The composition of claim 68 wherein the ~~vaccine composition~~ further comprises an additional antigen of another porcine pathogen.

73. (Currently amended) ~~A vaccine~~ The composition of claim 72 wherein the additional antigen of another porcine pathogen is selected from the group consisting of: an antigen of PRRS virus, an antigen of *Mycoplasma hypopneumoniae*, an antigen of *Actinobacillus pleuropneumoniae*, an antigen of *E. coli*, an antigen of Atrophic Rhinitis, an antigen of

PATENT  
454313-2338.1

Pseudorabies virus, an antigen of Hog cholera, an antigen of Swine Influenza, and combinations thereof.

74. (Currently amended) ~~A-vaccine~~ The composition of claim 72 wherein the additional antigen of another porcine pathogen is an antigen of PRRS virus.

75. (Currently amended) ~~A-vaccine~~ The composition of claim 69 wherein the porcine circovirus type II antigen is an attenuated virus porcine circovirus type II.

76. (Currently amended) ~~A-vaccine~~ The composition of claim 75 further comprising a veterinarily acceptable adjuvant.

77. (Currently amended) ~~A-vaccine~~ The composition of claim 75 further comprising a freeze-drying stabilizer.

78. (Currently amended) ~~A-vaccine~~ The composition of claim 69 wherein the porcine circovirus type II antigen is an inactivated porcine circovirus type II.

79. (Currently amended) ~~A-vaccine~~ The composition of claim 78 further comprising a veterinarily acceptable adjuvant.

80. (Currently amended) ~~A-vaccine~~ The composition according to claim 68 wherein the antigen of porcine circovirus comprises antigens of a plurality of porcine circoviruses.

81. (Currently amended) ~~A-vaccine~~ The composition of claim 69 wherein the ~~vaccine~~ composition further comprises an additional antigen of another porcine pathogen.

82. (Currently amended) ~~A-vaccine~~ The composition of claim 81 wherein the additional antigen of another porcine pathogen is selected from the group consisting of: an antigen of PRRS virus, an antigen of *Mycoplasma hyopneumoniae*, an antigen of *Actinobacillus pleuropneumoniae*, an antigen of *E. coli*, an antigen of Atrophic Rhinitis, an antigen of Pseudorabies virus, an antigen of Hog cholera, an antigen of Swine Influenza, and combinations thereof.

83. (Currently amended) ~~A-vaccine~~ The composition of claim 82 wherein the additional antigen of another porcine pathogen is an antigen of PRRS virus.

84. (Currently amended) A method for inoculating against porcine parvovirus and porcine circovirus comprising administering to a porcine ~~a-vaccine~~ the composition as claimed in claim 68.

PATENT  
454313-2338.1

85. (Currently amended) A kit for preparing a vaccine the composition of claim 68 comprising (i) the at least one porcine parvovirus antigen and (ii) the at least one porcine circovirus antigen, wherein (i) and (ii) are packaged separately.

86. (Previously presented) The kit of claim 85 wherein the porcine circovirus antigen comprises at least one porcine circovirus type II antigen.